NeoGenomics, Inc.
(NASDAQ : NEO)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Services » Medical Or Nursing Services
symbolcompany%chnglast%shortavg$volume
DVADaVita, Inc.
2.74%70.823.0%$117.91m
GHGuardant Health, Inc.
3.44%80.010.0%$89.54m
SDCSmileDirectClub, Inc.
-3.26%8.600.0%$48.90m
AMEDAmedisys, Inc.
1.05%152.8511.5%$42.64m
NVTAInvitae Corp.
7.65%18.722.6%$39.67m
CHEChemed Corp.
-1.40%407.1610.1%$36.76m
MDMEDNAX, Inc.
2.22%26.6811.2%$35.36m
LHCGLHC Group, Inc.
0.62%129.712.9%$26.41m
ACHCAcadia Healthcare Co., Inc.
1.88%31.5027.2%$24.43m
HNGRHanger, Inc.
2.33%24.110.0%$21.20m
TVTYTivity Health, Inc.
6.31%21.329.2%$16.34m
NEONeoGenomics, Inc.
2.51%24.076.1%$15.73m
ADUSAddus HomeCare Corp.
0.13%84.371.2%$13.18m
USPHU.S. Physical Therapy, Inc.
-0.54%114.334.7%$12.56m
ENSGThe Ensign Group, Inc.
1.75%41.405.8%$9.30m

Company Profile

NeoGenomics, Inc. is a clinical laboratory, which specializes in cancer genetics diagnostic testing and pharma services. It operates through the following two segments: Clinical and Pharma Services. The Clinical Services segment offers clinical cancer testing services to community-based pathologists. The Pharma Services segments supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. The Clinical Services Segment provides various clinical testing services to community-based pathology practices, hospital pathology labs and academic centers with reimbursement from various payers including client direct billing, commercial insurance, Medicare and other government payers, and patients. The Pharma Services segment: provides comprehensive testing services in supports pharmaceutical clients' oncology programs from discovery to commercialization. Its services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, immunohistochemistry, anatomic pathology and molecular genetic testing. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.